Musaffa Logo

Our certifications

Independent proof that every stock and portfolio meets halal standards.

How we screen every stock
METHODOLOGY

How we screen every stock

Our 5-step halal methodology, in 90 seconds.

FDMT Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 21, 2026

Report Source: 2026 1st Quarter Report

Analyst's Ratings for 4D Molecular Therapeutics Inc (FDMT)

Based on 17 analysts giving stock ratings to 4D Molecular Therapeutics Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
29
Buy
53
Hold
18
Sell
0
Strong Sell
0
4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc. Stock Analysis FDMT

United States Health Care Small Cap Report:
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. The company is headquartered in Emeryville, California and currently employs 196 full-time employees. The company went IPO on 2020-12-11. The firm's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The firm is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The firm's non-core programs include 4D-175, 4D-725, and 4D-310.
Read More

4D Molecular Therapeutics Inc (FDMT) Chart

Key Statistics of 4D Molecular Therapeutics Inc (FDMT)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$10.22$12.18

Today's Open

$10.22

Volume

2.07M

P/E Ratio (TTM)

-

52 Week Range

$3.68$12.34

Market Cap

454.28M

Avg. Volume

974.39K

Dividend Yield

-

Financial Metrics & Statements of 4D Molecular Therapeutics Inc (FDMT)

FAQ's for 4D Molecular Therapeutics Inc (FDMT)

  • According to Musaffa’s Shariah screening methodology, 4D Molecular Therapeutics Inc (FDMT) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes 4D Molecular Therapeutics Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in 4D Molecular Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of 4D Molecular Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of 4D Molecular Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of 4D Molecular Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.